Supplemental material
Research Paper
A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
Tino F. Schwarza Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Standort Juliusspital, Würzburg, GermanyCorrespondence[email protected]
https://orcid.org/0000-0003-1505-1823View further author information
https://orcid.org/0000-0003-1505-1823View further author information, , , Falko Panzerd Practice for Pediatric and Adolescent Medicine, Mannheim, Germanyhttps://orcid.org/0000-0002-3254-3881View further author information
https://orcid.org/0000-0002-3254-3881View further author information, , , Sylviane Ponceletf GSK, Wavre/Rixensart, Belgiumhttps://orcid.org/0000-0002-2279-5444View further author information
https://orcid.org/0000-0002-2279-5444View further author information, Naveen Karkadaf GSK, Wavre/Rixensart, Belgiumhttps://orcid.org/0000-0002-7543-1345View further author information
https://orcid.org/0000-0002-7543-1345View further author information, Nicolas Folschweillerf GSK, Wavre/Rixensart, Belgiumhttps://orcid.org/0000-0003-0299-7783View further author information
https://orcid.org/0000-0003-0299-7783View further author information, Lan Linf GSK, Wavre/Rixensart, Belgiumhttps://orcid.org/0000-0001-6604-918XView further author information
https://orcid.org/0000-0001-6604-918XView further author information, & Frank Struyff GSK, Wavre/Rixensart, Belgiumhttps://orcid.org/0000-0001-9988-0260View further author information
https://orcid.org/0000-0001-9988-0260View further author information show allRelated Research Data
Stillbirths: rates, risk factors, and acceleration towards 2030
Source:
Elsevier BV
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine
Source:
Informa UK Limited
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries
Source:
Oxford University Press (OUP)
Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study
Source:
Informa UK Limited
In this month’s Bulletin
Source:
WHO Press
Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors
Source:
Oxford University Press (OUP)
Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years
Source:
Elsevier BV
Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends
Source:
Elsevier BV
Results on exposure during pregnancy from a pregnancy registry for AS04-HPV-16/18 vaccine
Source:
Elsevier BV
In this month’s Bulletin
Source:
WHO Press
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
Source:
Elsevier BV
Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study
Source:
Elsevier BV
A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women
Source:
Oxford University Press (OUP)
Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types
Source:
Informa UK Limited
High incidence of cervical human papillomavirus infection in women during their first sexual relationship
Source:
Wiley
Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls
Source:
Elsevier BV
A new look at the statistical model identification
Source:
Institute of Electrical and Electronics Engineers (IEEE)
In this month’s Bulletin
Source:
WHO Press
Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
Source:
Elsevier BV
A new look at the statistical model identification
Source:
Institute of Electrical and Electronics Engineers (IEEE)
Congenital Malformations in the Newborn Population: A Population Study and Analysis of the Effect of Sex and Prematurity
Source:
Elsevier BV
Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
Source:
Elsevier BV
Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial
Source:
Oxford University Press (OUP)
In this month’s Bulletin
Source:
WHO Press
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
Source:
Elsevier BV
In this month’s Bulletin
Source:
WHO Press
In this month’s Bulletin
Source:
WHO Press
In this month’s Bulletin
Source:
WHO Press
In this month’s Bulletin
Source:
WHO Press
In this month’s Bulletin
Source:
WHO Press
In this month’s Bulletin
Source:
WHO Press
In this month’s Bulletin
Source:
WHO Press
In this month’s Bulletin
Source:
WHO Press
In this month’s Bulletin
Source:
WHO Press
In this month’s Bulletin
Source:
WHO Press
In this month’s Bulletin
Source:
WHO Press
HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future
Source:
Springer Nature
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
Source:
Elsevier BV
Long-term Immunogenicity and Safety of the HPV-16/18 AS04-adjuvanted Vaccine in 10- to 14-year-old Girls
Source:
Ovid Technologies (Wolters Kluwer Health)
Ectopic pregnancy
Source:
BMJ
Linking provided by
